Delving into the Latest Updates on EOS (Ethical Oncology Science) with Synapse

An Open-Label, Dose-escalation, Phase I Study to Determine the Maximum Tolerated Dose, Recommended Dose, Pharmacokinetics, and Pharmacodynamics of the Proteosome Inhibitor CEP 18770 Given Intravenously as Single Agent in Patients With Advanced Solid Tumours or Non-Hodgkin's Lymphomas

This Phase 1 escalating-dose study is designed to assess, the safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel proteasome inhibitor CEP 18770, given intravenously as single agent, in patients with advanced, incurable solid tumours or NHL, and to identify the recommended dose of CEP 18770 to be used in Phase 2 studies.

开始日期2007-11-01

申办/合作机构

EOS (Ethical Oncology Science)

100 项与 EOS (Ethical Oncology Science) 相关的临床结果

登录后查看更多信息

0 项与 EOS (Ethical Oncology Science) 相关的专利（医药）

登录后查看更多信息

100 项与 EOS (Ethical Oncology Science) 相关的药物交易

登录后查看更多信息

100 项与 EOS (Ethical Oncology Science) 相关的转化医学

登录后查看更多信息